Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial.

BACKGROUND: The effectiveness of glucosamine sulfate as a symptom and disease modifier for osteoarthritis is still under debate. OBJECTIVE: To assess whether glucosamine sulfate has an effect on the symptoms and structural progression of hip osteoarthritis during 2 years of treatment. DESIGN: Randomized, controlled trial. SETTING: Primary care in the Netherlands. PATIENTS: 222 patients with hip osteoarthritis who were recruited by their general practitioner. Patients were eligible if they met the American College of Rheumatology clinical criteria for hip osteoarthritis. INTERVENTION: 2 years of treatment with 1500 mg of oral glucosamine sulfate or placebo once daily. MEASUREMENTS: Primary outcome measures were Western Ontario and McMaster Universities (WOMAC) pain and function subscales over 24 months and joint space narrowing after 24 months. The main secondary outcome measures were WOMAC pain, function, and stiffness after 3, 12, and 24 months. RESULTS: At baseline, both groups were similar in demographic and clinical variables. Overall, WOMAC pain did not differ (mean difference [glucosamine sulfate minus placebo], -1.54 [95% CI, -5.43 to 2.36]), nor did WOMAC function (mean difference, -2.01 [CI, -5.38 to 1.36]). Joint space narrowing also did not differ after 24 months (mean difference, -0.029 [CI, -0.122 to 0.064]). Only 1 of the sensitivity analyses, based on extreme assumptions regarding missing assessments due to total hip replacement, provided results consistent with a glucosamine effect. LIMITATIONS: Twenty patients had total hip replacement during the trial. Half of the patients had a Kellgren and Lawrence score of 1. CONCLUSION: Glucosamine sulfate was no better than placebo in reducing symptoms and progression of hip osteoarthritis. International Standard Randomised Controlled Trial Number: ISRCTN54513166.

Repeated ankle sprains and delayed neuromuscular response: acceleration time parameters.

STUDY DESIGN: A comparative study. OBJECTIVES: To assess whether in subjects with unilateral chronic ankle instability the dynamic reaction time of the affected ankle differs from the healthy ankle and from ankles of a control group. BACKGROUND: Reaction time is an essential element in joint protection against sudden unexpected excessive movement requiring fast and coordinated muscle action. During a sudden ankle inversion movement, a reflex action of the evertor muscles is needed to counteract the movement. Adequate neuromuscular response is crucial and a delayed response could contribute to inversion trauma and subsequently to chronic ankle instability. The isokinetic dynamometer acceleration time (ACC-TIME) provides valuable information on dynamic neuromuscular ability. MATERIAL AND METHODS: Patients with unilateral chronic ankle instability (n = 11) and healthy individuals in a control group (n = 11) were tested on an isokinetic dynamometer during 3 sets of 3 reciprocal inversion/eversion movements of both ankles at 30 degrees/s and 120 degrees/s. Analysis of variance models were used to compare the ACC-TIME of the affected ankle to the unaffected ankle of the same subjects and a control group. RESULTS: For the evertor muscles at 30 degrees/s and 120 degrees/s a significantly prolonged ACC-TIME was found when comparing the affected ankles to the contralateral ankles and both ankles of the control group. For the invertor muscles at 120 degrees/s a significantly prolonged ACC-TIME was found when comparing the affected ankle to the unaffected ankles of patients and those of the control group. CONCLUSIONS: Because the most important evertor muscles are innervated by the fibular nerve, the significantly prolonged ACC-TIME of the affected ankle is consistent with the finding of a lower motor nerve conduction velocity of the fibular nerve after inversion trauma. The results support the concept of a delayed neuromuscular response as an important factor in the etiology of chronic ankle instability.

The effect of glucosamine sulphate on osteoarthritis: design of a long-term randomised clinical trial [ISRCTN54513166].

BACKGROUND: Pharmacological treatment for osteoarthritis (OA) can be divided into two groups: symptom-modifying drugs and disease-modifying drugs. Symptom-modifying drugs are currently the prescription of choice for patients with OA, as disease-modifying drugs are not yet available in usual care. However, there has recently been a lot of debate about glucosamine sulphate (GS), a biological agent that is thought to have both symptom-modifying and disease-modifying properties. This assumption has yet to be proved. The objective of this article is to present the design of a blind randomised clinical trial that examines the long-term symptom-modifying and disease-modifying effectiveness of GS in patients with hip OA. This trial is ongoing and will finish in March 2006. METHODS/DESIGN: Patients with hip OA meeting the ACR-criteria are randomly allocated to either 1500 mg of oral GS or placebo for the duration of two years. The primary outcome measures, which are joint space narrowing (JSN), and change in the pain and function score of the Western Ontario McMaster Universities Osteoarthritis index (WOMAC), are determined at baseline and after two years of follow-up during the final assessment. Intermediate measures at three-month intervals throughout the trial are used to study secondary outcome measures. Secondary outcome measures are changes in WOMAC stiffness score, quality of life, medical consumption, side effects and differences in biomarker CTX-II.